Merck bags a PhIII CMV victory in the wake of a flop at rival Chimerix
Four years after bagging the late-stage drug letermovir in a $571 million deal, Merck says the drug has come through in a lengthy Phase III study for preventing CMV infection in high-risk allogeneic hematopoietic stem cell transplant recipients.
Merck $MRK bagged letermovir back in 2012, when Roger Pomerantz was head of the pharma giant’s infectious disease group, paying Bayer spinoff AiCuris $142 million upfront and promising $429 million more in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
